AstraZeneca
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Study Measuring Effects on Intima Media Thickness: An Evaluation of Rosuvastatin 40 mg (METEOR)
- Conditions
- First Posted Date
- 2005-09-26
- Last Posted Date
- 2010-11-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 840
- Registration Number
- NCT00225589
- Locations
- 🇳🇴
Research Site, Skedsmokorset, Norway
Seroquel on Glucose Metabolism
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 572
- Registration Number
- NCT00214578
- Locations
- 🇬🇧
Research Site, Birmingham, United Kingdom
GALLANT 6 Tesaglitazar vs. Pioglitazone
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2010-11-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1450
- Registration Number
- NCT00214565
- Locations
- 🇦🇷
Research Sites, Quilmes - Buenos Aires, Argentina
🇬🇧Research Site, Wiltshire, United Kingdom
🇬🇧Research SIte, Reading, United Kingdom
LUNAR IIIb Study Comparing Rosuvastatin and Atorvastatin in Subjects With Acute Coronary Syndromes
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2010-11-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 825
- Registration Number
- NCT00214630
- Locations
- 🇵🇦
Research Site, Panama City, Panama
Type III Dysbetalipoproteinemia
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2010-11-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT00214604
- Locations
- 🇿🇦
Research Site, Cape Town, South Africa
GALLANT 5 Tesaglitazar Versus Metformin
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2010-11-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 580
- Registration Number
- NCT00214591
- Locations
- 🇬🇧
Research Sites, Northampton, United Kingdom
🇺🇸Research Center, Sherwood, Arizona, United States
🇬🇧Research Site, Wiltshire, United Kingdom
A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2009-03-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1600
- Registration Number
- NCT00206167
- Locations
- 🇷🇴
Research Site, Iasi, Romania
A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients Without Erosive Esophagitis.
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1400
- Registration Number
- NCT00206284
- Locations
- 🇬🇧
Research Site, Woking, United Kingdom
NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2009-03-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 120
- Registration Number
- NCT00206180
- Locations
- 🇺🇸
Research Site, Milwaukee, Wisconsin, United States
A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2009-03-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1500
- Registration Number
- NCT00206154
- Locations
- 🇿🇦
Research Site, Umkomaas, South Africa